BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28445808)

  • 1. Treatment results in children with myeloid leukemia of Down syndrome in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Jastaniah W; Alsultan A; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Abrar MB; Al Sudairy R; Al Ghemlas I
    Leuk Res; 2017 Jul; 58():48-54. PubMed ID: 28445808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
    Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
    Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study.
    Jastaniah W; Alsultan A; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Abrar MB; Al Sudairy R; Al Ghemlas I
    Hematology; 2018 Jul; 23(6):316-323. PubMed ID: 29212418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
    J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.
    Blink M; Zimmermann M; von Neuhoff C; Reinhardt D; de Haas V; Hasle H; O'Brien MM; Stark B; Tandonnet J; Pession A; Tousovska K; Cheuk DK; Kudo K; Taga T; Rubnitz JE; Haltrich I; Balwierz W; Pieters R; Forestier E; Johansson B; van den Heuvel-Eibrink MM; Zwaan CM
    Haematologica; 2014 Feb; 99(2):299-307. PubMed ID: 23935021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
    Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
    Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Leukemia in Down Syndrome Children in Hong Kong: Retrospective Review.
    Lam GK; Leung AW; Ha SY; Luk CW; Li CH; Ling SC; Chiang AK; Li CK
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):102-6. PubMed ID: 26808367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Jastaniah W; Al Ghemlas I; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Alsultan A; Abrar MB; Al Sudairy R
    Leuk Res; 2016 Oct; 49():66-72. PubMed ID: 27580158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Prognostic Factors That Influence Outcome of Childhood Acute Myeloid Leukemia in First Relapse in Saudi Arabia: Results of the Multicenter SAPHOS Study.
    Jastaniah W; Bayoumy M; Alsultan A; Al Daama S; Ballourah W; Al-Anzi F; Al Shareef O; Al Sudairy R; Abrar MB; Al Ghemlas I
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):773-780. PubMed ID: 30340992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
    O'Brien MM; Taub JW; Chang MN; Massey GV; Stine KC; Raimondi SC; Becton D; Ravindranath Y; Dahl GV;
    J Clin Oncol; 2008 Jan; 26(3):414-20. PubMed ID: 18202418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
    Pennella CL; Rossi JG; Baialardo EM; Alonso CN; Guitter MR; Sánchez La Rosa CG; Millán NC; Alfaro EM; Zubizarreta PA; Felice MS
    Arch Argent Pediatr; 2018 Aug; 116(4):e500-e507. PubMed ID: 30016023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes of myeloid leukemia associated with Down syndrome and de novo acute myeloid leukemia in children: Experience from a single tertiary center in Thailand.
    Songthawee N; Sripornsawan P; Chavananon S; Kittivisuit S; McNeil EB; Chotsampancharoen T
    Pediatr Hematol Oncol; 2024; 41(2):150-162. PubMed ID: 38013232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
    Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
    Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.
    Lange BJ; Kobrinsky N; Barnard DR; Arthur DC; Buckley JD; Howells WB; Gold S; Sanders J; Neudorf S; Smith FO; Woods WG
    Blood; 1998 Jan; 91(2):608-15. PubMed ID: 9427716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
    Gamis AS
    Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
    Barbaric D; Alonzo TA; Gerbing RB; Meshinchi S; Heerema NA; Barnard DR; Lange BJ; Woods WG; Arceci RJ; Smith FO
    Blood; 2007 Mar; 109(6):2314-21. PubMed ID: 17158236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and survival of children with acute leukemia with Down syndrome or other birth defects in New York State.
    Qiao B; Austin AA; Schymura MJ; Browne ML
    Cancer Epidemiol; 2018 Dec; 57():68-73. PubMed ID: 30326394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome for Down syndrome patients with hematopoietic disorders.
    Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
    J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.